Data gathered: January 2
Alternative Data for Century Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 78 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 401 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Century Therapeutics
None
| Price | $1.02 |
| Target Price | Sign up |
| Volume | 374,140 |
| Market Cap | $86M |
| Year Range | $1 - $3.37 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Drop in Short InterestJanuary 1 - ETF Daily News |
 |
Equities Research Analysts’ Price Target Changes for December 30th (AHR, ALGT, AMC, BBAI, CPX, EGP, IPSC, LUV, ONDS, OTEX)December 30 - ETF Daily News |
|
Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper SandlerDecember 30 - ETF Daily News |
 |
Century Therapeutics price target lowered by $8 at Piper Sandler, here's whyDecember 30 - Thefly.com |
 |
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25 - Yahoo |
|
Century Therapeutics, Inc. (NASDAQ:IPSC) Holdings Lowered by Cornercap Investment Counsel Inc.November 20 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 790,000 | 8.4M | -7.6M | -31M | -35M | -0.370 |
| Q2 '24 | 770,000 | 8.3M | -7.5M | -31M | -32M | -0.380 |
| Q1 '24 | 860,000 | 8.7M | -7.9M | -28M | -28M | -0.450 |
| Q4 '23 | 270,000 | 21M | -20M | -39M | -27M | -0.650 |
| Q3 '23 | 150,000 | 9M | -8.8M | -33M | -28M | -0.550 |
Insider Transactions View All
| Carr Douglas filed to sell 317,147 shares at $1.2. November 5 '24 |
| Farid Adrienne filed to sell 135,130 shares at $1.2. November 5 '24 |
| Quimi Daphne filed to buy 5,000 shares at $1.5. September 16 '24 |
| Carr Douglas filed to sell 334,041 shares at $1.8. August 7 '24 |
| Farid Adrienne filed to sell 136,163 shares at $1.8. August 7 '24 |
Similar companies
Read more about Century Therapeutics (IPSC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Century Therapeutics?
The Market Cap of Century Therapeutics is $86M.
What is the current stock price of Century Therapeutics?
Currently, the price of one share of Century Therapeutics stock is $1.02.
How can I analyze the IPSC stock price chart for investment decisions?
The IPSC stock price chart above provides a comprehensive visual representation of Century Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Century Therapeutics shares. Our platform offers an up-to-date IPSC stock price chart, along with technical data analysis and alternative data insights.
Does IPSC offer dividends to its shareholders?
As of our latest update, Century Therapeutics (IPSC) does not offer dividends to its shareholders. Investors interested in Century Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Century Therapeutics?
Some of the similar stocks of Century Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.